Supernus Pharmaceuticals Inc（SUPN）股票分析SUPNSupernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Supernus Pharmaceuticals Inc is currently not a strong buy due to significant recent losses and negative technical indicators. The current price is $37.88, and the stock has a 5-day change of -11.23%. Additionally, the RSI is extremely low at 13.38, indicating oversold conditions, but this also suggests potential for a rebound. However, the company reported a net loss exceeding $58 million in Q2 2026, contrasting sharply with a net income of $22.5 million in Q2 2025, highlighting ongoing financial struggles. The main risk is the insider selling, which increased by 2510.70% over the last month, signaling a lack of confidence among insiders. Therefore, while the stock may have potential long-term upside due to the merger with Indivior, the current financial and technical indicators suggest a hold position for now.

8 analysts cover SUPN: 6 rate it Buy, 2 Hold and 0 Sell. The average price target is 61.33.